Kim Francis, Dezfulian Cameron, Empey Philip E, Morrell Matthew, Olsufka Michele, Scruggs Sue, Kudenchuk Peter, May Susanne, Maynard Charles, Sayre Michael R, Nichol Graham
Department of Medicine, Harborview Medical Center, University of Washington, Seattle, Washington.
Department of Critical Care Medicine, Safar Center for Resuscitation Research and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
Am J Cardiol. 2018 Aug 15;122(4):554-559. doi: 10.1016/j.amjcard.2018.04.060. Epub 2018 Jun 20.
It is hypothesized that intravenous (IV) sodium nitrite given during resuscitation of out-of-hospital cardiac arrest (OHCA) will improve survival. We performed a phase 1 open-label study of IV sodium nitrite given during resuscitation of 120 patents with OHCA from ventricular fibrillation or nonventricular fibrillation initial rhythms by Seattle Fire Department paramedics. A total of 59 patients received 25 mg (low) and 61 patients received 60 mg (high) of sodium nitrite during resuscitation from OHCA. Treatment effects were compared between high- and low-dose nitrite groups, and all patients in a concurrent local Emergency Medical Services registry of OHCA. Whole blood nitrite levels were measured in 97 patients. The rate of return of spontaneous circulation (48% vs 49%), rearrest in the field (15% vs 25%), use of norepinephrine (12% vs 12%), first systolic blood pressure (124 ± 32 vs 125 ± 38 mm Hg), survival to discharge (23.7% vs 16.4%), and neurologically favorable survival (18.6% vs 11.5%) were not significantly different in the low and high nitrite groups. There were no significant differences in these outcomes among patients who received IV nitrite compared with concurrent registry controls. We estimate that 60 mg achieves whole blood nitrite levels of 22 to 38 μM 10 minutes after administration, whereas 25 mg achieves a level of 9 to 16 μM 10 minutes after delivery. In conclusion, administration of IV nitrite is feasible and appears to be safe in patients with OHCA, permitting subsequent evaluation of the effectiveness of IV nitrite for the treatment of OHCA.
据推测,在院外心脏骤停(OHCA)复苏期间静脉注射亚硝酸钠可提高生存率。我们进行了一项1期开放标签研究,由西雅图消防部门护理人员对120例因室颤或非室颤初始心律导致OHCA的患者在复苏期间静脉注射亚硝酸钠。共有59例患者在OHCA复苏期间接受了25mg(低剂量)亚硝酸钠,61例患者接受了60mg(高剂量)亚硝酸钠。比较了高剂量和低剂量亚硝酸钠组之间的治疗效果,并与同期当地OHCA紧急医疗服务登记处的所有患者进行了比较。对97例患者测量了全血亚硝酸盐水平。低剂量和高剂量亚硝酸钠组在自主循环恢复率(48%对49%)、现场再次骤停率(15%对25%)、去甲肾上腺素使用率(12%对12%)、首次收缩压(124±32对125±38mmHg)、出院生存率(23.7%对16.4%)以及神经功能良好生存率(18.6%对11.5%)方面无显著差异。与同期登记对照相比,接受静脉注射亚硝酸钠的患者在这些结果上也无显著差异。我们估计,60mg亚硝酸钠在给药10分钟后可使全血亚硝酸盐水平达到22至38μM,而25mg在给药10分钟后可使水平达到9至16μM。总之,对OHCA患者静脉注射亚硝酸钠是可行的,且似乎是安全的,这使得后续能够评估静脉注射亚硝酸钠治疗OHCA的有效性。